Concepedia

Di An

DA

Statistics

Publications

18

Citations

4.2K

H-Index

15

Active since

2007

Affiliations

Gilead Sciences (United States)(Current)

Texas Liver Institute

The University of Texas at San Antonio Health Science Center

University of Pennsylvania

University of Colorado Denver

Di An is an author at Gilead Sciences (United States) specializing in antiviral therapy, virology, and viral hepatitis.

ORCID

Publications per year

2007–2023

18

Publications

18

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Kris V. Kowdley, Stuart C. Gordon, K. Rajender Reddy et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

, , +13

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

Ira M. Jacobson, Stuart C. Gordon, Kris V. Kowdley et al. · New England Journal of Medicine · 2013 · 1.1K citations · Full text

, , +15

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

Michael P. Curry, Jacqueline G. O’Leary, Natalie Bzowej et al. · New England Journal of Medicine · 2015 · 806 citations · Full text

, , +17

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

Kris V. Kowdley, Eric Lawitz, Israel Crespo et al. · The Lancet · 2013 · 296 citations

, , +15

Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection

Edward Gane, Robert H. Hyland, Di An et al. · Gastroenterology · 2015 · 212 citations

, , +12

1–5 of 18